Immunologic Dose-Response to Adenovirus-Vectored Vaccines in Animals and Humans: A Systematic Review of Dose-Response Studies of Replication Incompetent Adenoviral Vaccine Vectors when Given via an Intramuscular or Subcutaneous Route

被引：15
作者：
Afrough, Sara [1 ]
Rhodes, Sophie [2 ]
Evans, Thomas [1 ]
White, Richard [2 ]
Benest, John [2 ]
机构：
[1] Vaccitech Ltd, Schrodinger Bldg,Heatley Rd,Oxford Sci Pk, Oxford OX4 4GE, England
[2] London Sch Hyg & Trop Med, Dept Infect Dis Epidemiol, Keppel St, London WC1E 7HT, England
来源：
VACCINES | 2020年 / 8卷 / 01期
基金：
英国生物技术与生命科学研究理事会; 英国医学研究理事会;
关键词：
dosing; dose-response; adenovirus-vectored vaccines; immunogenicity; clinical; pre-clinical; CD8(+) T-CELLS; PROTECTIVE IMMUNITY; MALARIA VACCINE; CLINICAL-ASSESSMENT; DOUBLE-BLIND; IMMUNOGENICITY; VIRUS; SAFETY; HIV-1; INDUCTION;
D O I：
10.3390/vaccines8010131
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
Optimal vaccine dosing is important to ensure the greatest protection and safety. Analysis of dose-response data, from previous studies, may inform future studies to determine the optimal dose. Implementing more quantitative modelling approaches in vaccine dose finding have been recently suggested to accelerate vaccine development. Adenoviral vectored vaccines are in advanced stage of development for a variety of prophylactic and therapeutic indications, however dose-response has not yet been systematically determined. To further inform adenoviral vectored vaccines dose identification, historical dose-response data should be systematically reviewed. A systematic literature review was conducted to collate and describe the available dose-response studies for adenovirus vectored vaccines. Of 2787 papers identified by Medline search strategy, 35 were found to conform to pre-defined criteria. The majority of studies were in mice or humans and studied adenovirus serotype 5. Dose-response data were available for 12 different immunological responses. The majority of papers evaluated three dose levels, only two evaluated more than five dose levels. The most common dosing range was 10(7)-10(10) viral particles in mouse studies and 10(8)-10(11) viral particles in human studies. Data were available on adenovirus vaccine dose-response, primarily on adenovirus serotype 5 backbones and in mice and humans. These data could be used for quantitative adenoviral vectored vaccine dose optimisation analysis.
引用
收藏
页数：12
相关论文
共 53 条
[41]  
Rodrigues EG, 1997, J IMMUNOL, V158, P1268
[42]   Biodistribution and toxicological safety of adenovirus type 5 and type 35 vectored vaccines against human immunodeficiency virus-1 (HIV-1), ebola, or marburg are similar despite differing adenovirus serotype vector, manufacturer's construct, or gene inserts [J].
Sheets, Rebecca L. ;
Stein, Judith ;
Bailer, Robert T. ;
Koup, Richard A. ;
Andrews, Charla ;
Nason, Martha ;
He, Bin ;
Koo, Edward ;
Trotter, Holly ;
Duffy, Chris ;
Manetz, T. Scott ;
Gomez, Phillip .
JOURNAL OF IMMUNOTOXICOLOGY, 2008, 5 (03) :315-335
[43]   A Candidate H1N1 Pandemic Influenza Vaccine Elicits Protective Immunity in Mice [J].
Steitz, Julia ;
Barlow, Peter G. ;
Hossain, Jaber ;
Kim, Eun ;
Okada, Kaori ;
Kenniston, Tom ;
Rea, Sheri ;
Donis, Ruben O. ;
Gambotto, Andrea .
PLOS ONE, 2010, 5 (05)
[44]   A novel alphavirus replicon-vectored vaccine delivered by adenovirus induces sterile immunity against classical swine fever [J].
Sun, Yuan ;
Li, Hong-Yu ;
Tian, Da-Yong ;
Han, Qiu-Ying ;
Zhang, Xin ;
Li, Na ;
Qiu, Hua-Ji .
VACCINE, 2011, 29 (46) :8364-8372
[45]   Functionally inactivated dominant viral antigens of human cytomegalovirus delivered in replication incompetent adenovirus type 6 vectors as vaccine candidates [J].
Tang, Aimin ;
Freed, Daniel C. ;
Li, Fengsheng ;
Meschino, Steve ;
Prokop, Michael ;
Bett, Andrew ;
Casimiro, Danilo ;
Wang, Dai ;
Fu, Tong-Ming .
HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2017, 13 (12) :2763-2771
[46]   Use of ChAd3-EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo: a phase 1, single-blind, randomised trial, a phase 1b, open-label and double-blind, dose-escalation trial, and a nested, randomised, double-blind, placebo-controlled trial [J].
Tapia, Milagritos D. ;
Sow, Samba O. ;
Lyke, Kirsten E. ;
Haidara, Fadima Cheick ;
Diallo, Fatoumata ;
Doumbia, Moussa ;
Traore, Awa ;
Coulibaly, Flanon ;
Kodio, Mamoudou ;
Onwuchekwa, Uma ;
Sztein, Marcelo B. ;
Wahid, Rezwanul ;
Campbell, James D. ;
Kieny, Marie-Paule ;
Moorthy, Vasee ;
Imoukhuede, Egeruan B. ;
Rampling, Tommy ;
Roman, Francois ;
De Ryck, Iris ;
Bellamy, Abbie R. ;
Dally, Len ;
Mbaya, Olivier Tshiani ;
Ploquin, Aurelie ;
Zhou, Yan ;
Stanley, Daphne A. ;
Bailer, Robert ;
Koup, Richard A. ;
Roederer, Mario ;
Ledgerwood, Julie ;
Hill, Adrian V. S. ;
Ballou, W. Ripley ;
Sullivan, Nancy ;
Graham, Barney ;
Levine, Myron M. .
LANCET INFECTIOUS DISEASES, 2016, 16 (01) :31-42
[47]   Beta-defensin 2 enhances immunogenicity and protection of an adenovirus-based H5N1 influenza vaccine at an early time [J].
Vemula, Sai V. ;
Amen, Omar ;
Katz, Jacqueline M. ;
Donis, Ruben ;
Sambhara, Suryaprakash ;
Mittal, Suresh K. .
VIRUS RESEARCH, 2013, 178 (02) :398-403
[48]   Recombinant low-seroprevalent adenoviral vectors Ad26 and Ad35 expressing the respiratory syncytial virus (RSV) fusion protein induce protective immunity against RSV infection in cotton rats [J].
Widjojoatmodjo, Myra N. ;
Bogaert, Lies ;
Meek, Bob ;
Zahn, Roland ;
Vellinga, Jort ;
Custers, Jerome ;
Serroyen, Jan ;
Radosevic, Katarina ;
Schuitemaker, Hanneke .
VACCINE, 2015, 33 (41) :5406-5414
[49]   A replication-defective human adenovirus recombinant serves as a highly efficacious vaccine carrier [J].
Xiang, ZQ ;
Yang, YP ;
Wilson, JM ;
Ertl, HCJ .
VIROLOGY, 1996, 219 (01) :220-227
[50]   Novel, chimpanzee serotype 68-based adenoviral vaccine carrier for induction of antibodies to a transgene product [J].
Xiang, ZQ ;
Gao, GP ;
Reyes-Sandoval, A ;
Cohen, CJ ;
Li, Y ;
Bergelson, JM ;
Wilson, JM ;
Ertl, HCJ .
JOURNAL OF VIROLOGY, 2002, 76 (06) :2667-2675
123456